Marshall Islands vs Mayotte: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Marshall Islands
0.9%
in 2024
Mayotte
0.8%
in 2024
Marshall Islands rank
35th
Mayotte rank
37th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Marshall Islands
- Mayotte
How they compare
Marshall Islands currently reports 0.9% against 0.8% in Mayotte, a difference of 0.1%.
That makes Marshall Islands's figure about 1.1 times Mayotte's.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Mayotte ahead.
Marshall Islands ranks 35th and Mayotte ranks 37th of 215 countries.
Marshall Islands has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Marshall Islands | Mayotte | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.4% | 1.2% | 0.1% | Marshall Islands |
| 2020s | 1.0% | 0.8% | 0.2% | Marshall Islands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Marshall Islands or Mayotte?
- Marshall Islands, at 0.9% against 0.8% in Mayotte as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Marshall Islands and Mayotte?
- 0.1%, with Marshall Islands ahead.
- How many years of comparable data are there for Marshall Islands and Mayotte?
- 10 years are reported by both, from 2015 to 2024.
- How do Marshall Islands and Mayotte rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Marshall Islands ranks 35th and Mayotte ranks 37th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.